18F-Sodium Fluoride (NaF)

DRUG2 trials

Sponsors

British Columbia Cancer Agency, University of Wisconsin, Madison

Conditions

Bone Metastases From Breast or Prostate CancerProstatic Neoplasms

Phase 3

18F-NaF PET Imaging for Bone Scintigraphy

CompletedNCT01930812

British Columbia Cancer AgencyBone Metastases From Breast or Prostate Cancer

Start: 2014-07-31End: 2019-03-31Updated: 2019-04-25

Unknown Phase

Imaging Biomarkers to Validate Response in Enzalutamide-Treated mCRPC

CompletedNCT02677376

University of Wisconsin, MadisonProstatic Neoplasms

Start: 2016-06-27End: 2020-01-03Updated: 2020-02-26

Related Papers

Intra-individual comparison of <sup>18</sup>F-sodium fluoride PET-CT and <sup>99m</sup>Tc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial.

2022-11-0429 citations

Targeting differential response using molecular guided biopsies in bone-metastatic prostate cancer.

Journal of Clinical Oncology2019-05-20